Literature DB >> 9485010

Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium.

W Zhang1, L R Kapusta, J M Slingerland, L H Klotz.   

Abstract

Telomerase is a ribonucleoprotein that synthesizes telomeric DNA on chromosomal ends. Telomerase activation has been seen in many immortal cell lines and cancers. Telomerase activity was analyzed in prostate carcinoma; in coexistent prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH), atrophy and normal tissue; and in benign prostate glands. Telomerase activity was detected in 80 of 87 (92%) prostate cancers. Forty-one matched samples (from a total of 32 cases) were available for comparative analysis. The presence of telomerase activity in adjacent PIN, BPH, and normal tissue was correlated with telomerase activity in the malignant epithelium. In these adjacent tissues, telomerase activity was found in 11 of 15 (73%) PINs, 13 of 26 (50%) BPHs, and 1 of 6 (16%) atrophy and 4 of 11 (36%) normal tissues. In contrast to the BPH tissue from cancer-bearing glands, all 16 BPH specimens from patients only diagnosed with BPH were telomerase activity negative. In cancer samples, there was no correlation between telomerase activity and Gleason grade or preoperation prostate-specific antigen level. Our data indicate that telomerase activity is present in most prostate cancers. The high rate of telomerase activity in the benign-appearing areas of these glands may be attributed either to the presence of occult cancer cells or to early molecular alterations of cancer that were histologically inapparent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485010

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.

Authors:  Simona Nanni; Michela Narducci; Linda Della Pietra; Fabiola Moretti; Annalisa Grasselli; Piero De Carli; Ada Sacchi; Alfredo Pontecorvi; Antonella Farsetti
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

3.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

4.  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.

Authors:  Yingming Li; Bahaa S Malaeb; Zhong-Ze Li; Melissa G Thompson; Zhi Chen; David R Corey; Jer-Tsong Hsieh; Jerry W Shay; Kenneth S Koeneman
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

5.  Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.

Authors:  Shuang Liu; Yanfeng Qi; Yubin Ge; Tamika Duplessis; Brian G Rowan; Clement Ip; Helen Cheng; Paul S Rennie; Izumi Horikawa; Arthur J Lustig; Qun Yu; Haitao Zhang; Yan Dong
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

6.  Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Authors:  Zhihu Ding; Chang-Jiun Wu; Mariela Jaskelioff; Elena Ivanova; Maria Kost-Alimova; Alexei Protopopov; Gerald C Chu; Guocan Wang; Xin Lu; Emma S Labrot; Jian Hu; Wei Wang; Yonghong Xiao; Hailei Zhang; Jianhua Zhang; Jingfang Zhang; Boyi Gan; Samuel R Perry; Shan Jiang; Liren Li; James W Horner; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Cell       Date:  2012-02-16       Impact factor: 41.582

7.  Telomerase activity in periampullary tumors correlates with aggressive malignancy.

Authors:  J H Balcom; T Keck; A L Warshaw; B Antoniu; F Graeme-Cook; C Fernández-del Castillo
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

8.  Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a).

Authors:  Pinar Atasoy; Erdal Yilmaz; Onder Bozdogan; Sebnem Ayva; Ertan Batislam
Journal:  Int Urol Nephrol       Date:  2008-06-03       Impact factor: 2.370

9.  Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia.

Authors:  Carlo Vicentini; Giovanni Luca Gravina; Adriano Angelucci; Esterina Pascale; Ettore D'Ambrosio; Paola Muzi; Gabriella Di Leonardo; Antonio Fileni; Andrea Tubaro; Claudio Festuccia; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-29       Impact factor: 4.553

10.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

Authors:  Simona Nanni; Valentina Benvenuti; Annalisa Grasselli; Carmen Priolo; Aurora Aiello; Stefania Mattiussi; Claudia Colussi; Vittoria Lirangi; Barbara Illi; Manuela D'Eletto; Anna Maria Cianciulli; Michele Gallucci; Piero De Carli; Steno Sentinelli; Marcella Mottolese; Paolo Carlini; Lidia Strigari; Stephen Finn; Elke Mueller; Giorgio Arcangeli; Carlo Gaetano; Maurizio C Capogrossi; Raffaele Perrone Donnorso; Silvia Bacchetti; Ada Sacchi; Alfredo Pontecorvi; Massimo Loda; Antonella Farsetti
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.